Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol-Myers Squibb	$60.00 +0.8%	$58.69	$39.35 ▼ $63.33	$121.90B	0.43	12.70 million shs	1.40 million shs
CRSP CRISPR Therapeutics	$34.18 +3.1%	$42.80	$32.48 ▼ $67.88	$2.92B	1.77	1.56 million shs	447,372 shs
GERN Geron	$1.57 +5.7%	$2.24	$1.45 ▼ $5.34	$990.39M	0.54	11.35 million shs	4.91 million shs
MRK Merck & Co., Inc.	$86.81 -0.4%	$91.57	$81.04 ▼ $134.63	$219.02B	0.35	11.07 million shs	2.15 million shs
VRTX Vertex Pharmaceuticals	$486.84 +0.4%	$478.85	$377.85 ▼ $519.88	$124.81B	0.41	1.28 million shs	169,154 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol-Myers Squibb	-2.49%	+0.53%	-0.29%	+5.25%	+12.39%
CRSP CRISPR Therapeutics	-2.62%	-18.95%	-24.54%	-15.80%	-51.39%
GERN Geron	-6.92%	-12.94%	-15.91%	-58.19%	-53.31%
MRK Merck & Co., Inc.	-2.97%	-0.92%	-5.59%	-12.47%	-33.49%
VRTX Vertex Pharmaceuticals	-0.02%	-4.77%	+1.03%	+20.37%	+15.28%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol-Myers Squibb	3.8788 of 5 stars	1.2	3.0	4.2	4.0	3.5	3.3	0.0
CRSP CRISPR Therapeutics	3.2444 of 5 stars	4.2	2.0	0.0	0.0	2.1	3.3	0.6
GERN Geron	4.3697 of 5 stars	4.4	4.0	0.0	1.3	1.7	3.3	0.6
MRK Merck & Co., Inc.	5 of 5 stars	4.3	5.0	5.0	3.9	3.3	3.3	3.8
VRTX Vertex Pharmaceuticals	3.9222 of 5 stars	2.3	3.0	0.0	3.3	3.5	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol-Myers Squibb	2.33	Hold	$57.86	-3.57% Downside
CRSP CRISPR Therapeutics	2.48	Hold	$73.11	113.88% Upside
GERN Geron	2.82	Moderate Buy	$5.75	267.41% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$117.12	34.91% Upside
VRTX Vertex Pharmaceuticals	2.65	Moderate Buy	$509.17	4.59% Upside

Current Analyst Ratings Breakdown

Latest GERN, VRTX, CRSP, BMY, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$408.00 ➝ $420.00
3/31/2025	VRTX Vertex Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$555.00 ➝ $567.00
3/12/2025	GERN Geron	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/12/2025	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
2/27/2025	GERN Geron	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$9.00 ➝ $4.00
2/27/2025	GERN Geron	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$6.00 ➝ $4.00
2/27/2025	GERN Geron	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
2/27/2025	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
2/27/2025	GERN Geron	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$3.50 ➝ $2.00
2/26/2025	GERN Geron	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
2/20/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$407.00 ➝ $408.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol-Myers Squibb	$48.30B	2.53	$6.33 per share	9.48	$8.08 per share	7.43
CRSP CRISPR Therapeutics	$35M	83.76	N/A	N/A	$22.52 per share	1.52
GERN Geron	$76.99M	12.95	N/A	N/A	$0.46 per share	3.40
MRK Merck & Co., Inc.	$64.17B	3.42	$3.01 per share	28.82	$14.85 per share	5.85
VRTX Vertex Pharmaceuticals	$11.02B	11.34	N/A	N/A	$63.90 per share	7.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	9.85	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.37	N/A	N/A	N/A	-981.54%	-18.46%	-15.79%	5/6/2025 (Estimated)
GERN Geron	-$184.13M	-$0.27	N/A	N/A	N/A	-682.48%	-67.53%	-45.46%	5/7/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.73	12.88	8.77	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$2.20	N/A	27.80	2.11	-4.86%	-2.02%	-1.49%	5/5/2025 (Estimated)

Latest GERN, VRTX, CRSP, BMY, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	BMY Bristol-Myers Squibb	$1.55	N/A	N/A	N/A	$10.77 billion	N/A
4/24/2025	N/A	MRK Merck & Co., Inc.	$2.16	N/A	N/A	N/A	$15.59 billion	N/A
2/26/2025	Q4 2024	GERN Geron	-$0.04	-$0.04	N/A	-$0.04	$45.29 million	$47.54 million
2/11/2025	Q4 2024	CRSP CRISPR Therapeutics	-$1.15	-$0.44	+$0.71	-$0.44	N/A	N/A
2/10/2025	Q4 2024	VRTX Vertex Pharmaceuticals	$3.99	$3.54	-$0.45	$3.50	$2.78 billion	N/A
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol-Myers Squibb	$2.48	4.13%	+6.38%	N/A	17 Years
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.24	3.73%	+5.73%	48.14%	14 Years
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest GERN, VRTX, CRSP, BMY, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol-Myers Squibb	2.90	1.25	1.15
CRSP CRISPR Therapeutics	N/A	22.07	22.07
GERN Geron	0.04	2.89	2.74
MRK Merck & Co., Inc.	0.79	1.36	1.15
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol-Myers Squibb	76.41%
CRSP CRISPR Therapeutics	69.20%
GERN Geron	73.71%
MRK Merck & Co., Inc.	76.07%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BMY Bristol-Myers Squibb	0.09%
CRSP CRISPR Therapeutics	4.10%
GERN Geron	3.10%
MRK Merck & Co., Inc.	0.09%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
CRSP CRISPR Therapeutics	473	85.77 million	82.26 million	Optionable
GERN Geron	70	636.90 million	585.76 million	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.79 million	256.28 million	Optionable

GERN, VRTX, CRSP, BMY, and MRK Headlines

Recent News About These Companies

Groupama Asset Managment Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 2 at 7:07 AM | marketbeat.com

Tweedy Browne Co LLC Sells 12,969 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 2 at 6:54 AM | marketbeat.com

Geode Capital Management LLC Sells 287,652 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 2 at 6:27 AM | marketbeat.com

Schroder Investment Management Group Has $65.35 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 2 at 4:49 AM | marketbeat.com

Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks

April 1 at 2:01 PM | cnbc.com

VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates

April 1 at 11:55 AM | zacks.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $567.00 at Bank of America

April 1 at 8:26 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Increased by B. Metzler seel. Sohn & Co. AG

April 1 at 6:57 AM | marketbeat.com

Colrain Capital LLC Acquires New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 1 at 6:50 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Reduced by Alliancebernstein L.P.

April 1 at 6:31 AM | marketbeat.com

AIA Group Ltd Cuts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 1 at 6:01 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Increased by Wellington Management Group LLP

April 1 at 5:53 AM | marketbeat.com

Bank of America Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $567.00

April 1 at 2:29 AM | americanbankingnews.com

Clearbridge Investments LLC Has $745.34 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 7:20 AM | marketbeat.com

Joseph Group Capital Management Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 6:31 AM | marketbeat.com

California Public Employees Retirement System Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 6:24 AM | marketbeat.com

Allstate Corp Makes New $3.07 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 5:11 AM | marketbeat.com

Blair William & Co. IL Has $10.73 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 4:37 AM | marketbeat.com

Vertex Pharmaceuticals: Advancements in T1D Program and Strategic Focus on Innovative Therapies Justify Buy Rating

March 30 at 11:03 PM | tipranks.com

Allianz SE Invests $9.59 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 30 at 7:19 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Pictet Asset Management Holding SA

March 30 at 5:53 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
2 Reasons to Buy Apple Stock and 1 Significant Risk
By Chris Markoch | April 2, 2025
View 2 Reasons to Buy Apple Stock and 1 Significant Risk

GERN, VRTX, CRSP, BMY, and MRK Company Descriptions

Bristol-Myers Squibb NYSE:BMY

$60.00 +0.45 (+0.75%)

As of 11:06 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

CRISPR Therapeutics NASDAQ:CRSP

$34.18 +1.04 (+3.14%)

As of 11:06 AM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Geron NASDAQ:GERN

$1.56 +0.09 (+5.74%)

As of 11:05 AM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Merck & Co., Inc. NYSE:MRK

$86.81 -0.31 (-0.35%)

As of 11:06 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Vertex Pharmaceuticals NASDAQ:VRTX

$486.84 +2.10 (+0.43%)

As of 11:06 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, VRTX, CRSP, BMY, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, VRTX, CRSP, BMY, and MRK Earnings

Compare Dividends

Latest GERN, VRTX, CRSP, BMY, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, VRTX, CRSP, BMY, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, VRTX, CRSP, BMY, and MRK Company Descriptions

Bristol-Myers Squibb NYSE:BMY

CRISPR Therapeutics NASDAQ:CRSP

Geron NASDAQ:GERN

Merck & Co., Inc. NYSE:MRK

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools